Serum Levels of Soluble ST2 and IL-10 Are Associated with Disease Severity in Patients with IgA Nephropathy

Journal of Immunology Research

Volumn 2016, Issue , 2016, Pages

  Zhang, Zhihui ^a   Wang, Haifeng ^a   Zhang, Li ^a   Crew, Rebecca ^b   Zhang, Nan ^a   Liu, Xiaolei ^a   Jiang, Yanfang ^a,c  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c Jiangsu Co Innov Ctr Prevention and Control Import Animal InfecDiseand Zoon   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 33; INTERLEUKIN 4; PHOSPHORUS; PREDNISOLONE; BIOLOGICAL MARKER; CYTOKINE;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL EXAMINATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOGENESIS; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; ADOLESCENT; BLOOD; GLOMERULONEPHRITIS, IGA; IMMUNOLOGY; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS; CYTOKINES; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; INTERLEUKIN-10; MALE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84998610791     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2016/6540937     Document Type: Article

References (35)

1. L.-S. Li and Z.-H. Liu, "Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies," Kidney International, vol. 66,no. 3, pp. 920-923, 2004.
2. J. V. Donadio and J. P. Grande, "IgA nephropathy," The New England Journal of Medicine, vol. 347, no. 10, pp. 738-748, 2002.
3. R. J. Wyatt andB. A. Julian, "IgAnephropathy,"TheNewEngland Journal of Medicine, vol. 368, no. 25, pp. 2402-2414, 2013.
4. G. D'Amico, "Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors," American Journal of Kidney Diseases, vol. 36, no. 2, pp. 227-237, 2000.
5. H. H. Yu, K. H. Chu, Y. H. Yang et al., "Genetics and immunopathogenesis of IgA nephropathy," Clinical Reviews in Allergy & Immunology, vol. 41, no. 2, pp. 198-213, 2011.
6. Y. Suzuki and Y. Tomino, "Potential immunopathogenic role of the mucosa-bone marrow axis in IgA nephropathy: insights from animal models," Seminars in Nephrology, vol. 28, no. 1, pp. 66-77, 2008.
7. H. Suzuki, R. Fan, Z. Zhang et al., "Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity," Journal of Clinical Investigation, vol. 119, no. 6, pp. 1668-1677, 2009.
8. M. Löhning, A. Stroehmann, A. J. Coyle et al., "T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important forTh2 effector function," Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 12, pp. 6930-6935, 1998.
9. S. Sanada, D. Hakuno, L. J. Higgins, E. R. Schreiter, A. N. J. McKenzie, and R. T. Lee, "IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system," Journal of Clinical Investigation, vol. 117, no. 6, pp. 1538-1549, 2007.
10. J. Schmitz, A. Owyang, E. Oldham et al., "IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines," Immunity, vol. 23, no. 5, pp. 479-490, 2005.
11. G. Palmer, D. Talabot-Ayer, C. Lamacchia et al., "Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis," Arthritis and Rheumatism, vol. 60, no. 3, pp. 738-749, 2009.
12. P. N. Pushparaj, H. K. Tay, S. C. H'ng et al., "The cytokine interleukin-33 mediates anaphylactic shock," Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 24, pp. 9773-9778, 2009.
13. D. Kalavrizioti, M. Gerolymos, M. Rodi et al., "T helper (Th)-cytokines in the urine of patients with primary glomerulonephritis treated with immunosuppressive drugs: can they predict outcome" Cytokine, vol. 76, no. 2, pp. 260-269, 2015.
14. A. Kuroki, M. Iyoda, T. Shibata, andT. Sugisaki, "Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy," Kidney International, vol. 68, no. 1, pp. 302-310, 2005.
15. K. N. Lai, R. T. Ho,C. K. Lai,C. H. Chan, and P. K. Li, "Increase of both circulating Th1 and Th2 T lymphocyte subsets in IgA nephropathy," Clinical & Experimental Immunology, vol. 96, no. 1, pp. 116-121, 1994.
16. S. H. Kang, S. R. Choi, H. S. Park et al., "The Oxford classification as a predictor of prognosis in patients with IgA nephropathy," Nephrology Dialysis Transplantation, vol. 27, no. 1, pp. 252-258, 2012.
17. E. Morgan, R. Varro, H. Sepulveda et al., "Cytometric bead array: amultiplexed assay platformwith applications in various areas of biology," Clinical Immunology, vol. 110, no. 3, pp. 252-266, 2004.
18. A. Tárnok, J. Hambsch, R. Chen, and R. Varro, "Cytometric bead array tomeasure six cytokines in twenty-five microliters of serum," Clinical Chemistry, vol. 49, no. 6, pp. 1000-1002, 2003.
19. H. E. Barksby, S. R. Lea, P. M. Preshaw, and J. J. Taylor, "The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders," Clinical and Experimental Immunology, vol. 149, no. 2, pp. 217-225, 2007.
20. F. Y. Liew, N. I. Pitman, and I. B. McInnes, "Disease-associated functions of IL-33: the new kid in the IL-1 family," Nature Reviews Immunology, vol. 10, no. 2, pp. 103-110, 2010.
21. J. Louten, A. L. Rankin, Y. Li et al., "Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation," International Immunopharmacology, vol. 23, no. 5, pp. 307-315, 2011.
22. Z. Yang, Y. Liang, W. Xi, C. Li, and R. Zhong, "Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population," Clinical and Experimental Medicine, vol. 11, no. 2, pp. 75-80, 2011.
23. J. C. Alves-Filho, F. Snego, F. O. Souto et al., "Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection," Nature Medicine, vol. 16, no. 6, pp. 708-712, 2010.
24. H. Hayakawa, M. Hayakawa, A. Kume, and S.-I. Tominaga, "Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation," Journal of Biological Chemistry, vol. 282, no. 36, pp. 26369-26380, 2007.
25. C. A. Dinarello, "An IL-1 family member requires caspase-1 processing and signals through the ST2 receptor," Immunity, vol. 23, no. 5, pp. 461-462, 2005.
26. M. Brunner, C. Krenn, G. Roth et al., "Increased levels of soluble ST2 protein and IgG1production in patients with sepsis and trauma," Intensive Care Medicine, vol. 30, no. 7, pp. 1468-1473, 2004.
27. M. Shimpo, D. A. Morrow, E. O. Weinberg et al., "Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction," Circulation, vol. 109, no. 18, pp. 2186-2190, 2004.
28. T. Mueller, B. Dieplinger, A. Gegenhuber, W. Poelz, R. Pacher, andM. Haltmayer, "Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure," Clinical Chemistry, vol. 54, no. 4, pp. 752-756, 2008.
29. R. Rodrigues-Dez, L. S. Aroeira, M. Orejudo et al., "IL-17A is a novel player in dialysis-induced peritoneal damage," Kidney International, vol. 86, no. 2, pp. 303-315, 2014.
30. Y. Liu, P. Zhao, Z. Qu, D. A. Ayana, and Y. Jiang, "Frequency of CD4+CXCR5+ TFH cells in patients with hepatitis b virus-associated membranous nephropathy," International Immunopharmacology, vol. 22, no. 1, pp. 98-106, 2014.
31. T. Stampalija, R. Romero, S. J. Korzeniewski et al., "Soluble ST2 in the fetal inflammatory response syndrome: in vivo evidence of activation of the anti-inflammatory limb of the immune response," The Journal of Maternal-Fetal & Neonatal Medicine, vol. 26, no. 14, pp. 1384-1393, 2013.
32. V. Lavi-Moshayoff, G. Wasserman, T. Meir, J. Silver, and T. Naveh-Many, "PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop," American Journal of Physiology-Renal Physiology, vol. 299, no. 4, pp. F882-F889, 2010.
33. D. Medici, M. S. Razzaque, S. DeLuca et al., "FGF-23-Klotho signaling stimulates proliferation and prevents Vitamin Dinduced apoptosis," Journal of Cell Biology, vol. 182, no. 3, pp. 459-465, 2008.
34. M. M. Zaiss, M. Kurowska-Stolarska, C. Böhm et al., "IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects fromTNF-mediated bone loss," The Journal of Immunology, vol. 186, no. 11, pp. 6097-6105, 2011.
35. Y.-S. Bao, S.-P. Na, P. Zhang et al., "Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patientswith chronic kidney disease," Journal of Clinical Immunology, vol. 32, no. 3, pp. 587-594, 2012.